



PharmaVISION

PharmaVISION

Educating Minds, Empowering Pharma

NOVEMBER 2025

Pharma and Healthcare Insights

Published by

PHARMA CLUB

IES's Management College and Research Centre, Mumbai

PharmaVISION

Indian Pharma Breaks Into China: Cipla, Natco and Hetero Win Major Generic Drug Supply Contracts

In a significant milestone for India's pharmaceutical sector, leading companies such as Cipla, Natco Pharma, Hetero Labs, and Annora Pharma have secured major supply contracts under China's latest Volume-Based Procurement (VBP) programme. This marks one of the largest collective wins for Indian generic-drug makers in the highly regulated Chinese market.

As part of the tender, Indian firms will supply seven key generic medicines across multiple therapeutic areas. A highlight of this achievement is the selection of Cipla and Hetero Labs to jointly deliver nearly one billion tablets of Dapagliflozin, a top-selling diabetes drug in China. Natco Pharma will supply Olaparib, an important oncology medication, while Annora Pharma has been awarded a contract for Oxcarbazepine, used in epilepsy management.



The VBP round covered 55 therapeutic categories and 453 products, making the competition exceptionally intense among 272 global companies. Winning these contracts demonstrates China's confidence in India's manufacturing quality, cost competitiveness, and supply reliability.

This development is being viewed as a strategic breakthrough for Indian pharma, opening doors to a market historically dominated by domestic and multinational players. It also signals new opportunities for India to diversify exports, expand global footprints, and strengthen its role as a trusted supplier of high-quality, affordable generic medicines.

Source: ET pharma

Lupin Launches First Long-Acting Injectable Using PrecisionSphere in the US



Lupin has introduced its long-acting Risperidone injectable in the US, marking the first commercial product developed using its proprietary PrecisionSphere™ LAI platform. The product has received 180-day Competitive Generic Therapy (CGT) exclusivity from the US FDA, offering Lupin a competitive market window. It is available in 25 mg, 37.5 mg, and 50 mg strengths and is bioequivalent to Risperdal Consta®. The therapy is approved for treating schizophrenia and for the maintenance of bipolar I disorder in adults.

PrecisionSphere technology enables uniform microspheres for smoother injectability and sustained drug release. This launch strengthens Lupin's position in complex generics and specialty injectables within the US market.

Source: ET Pharma.com

J&J Makes Major Oncology Push with Halda's \$3.05 Billion Takeover



Johnson & Johnson is acquiring Halda Therapeutics for \$3.05 billion. Halda is a clinical-stage biotech company known for its innovative RIPTAC “hold-and-kill” cell death technology. RIPTACs are bifunctional small molecules that selectively destroy cancer cells. J&J is particularly interested in Halda's lead drug candidate HLD-0915. HLD-0915 is an oral therapy for metastatic castration-resistant prostate cancer (mCRPC). Early Phase 1/2 trials have shown PSA reductions and tumor responses in heavily pre-treated patients.

Halda's platform also includes programs for breast, lung, and other solid tumors. The deal fits J&J's strategy to invest in next-generation cancer technologies. It will help the company address the growing demand for targeted cancer therapies. The acquisition strengthens J&J's long-term competitiveness as patents expire. Regulatory approval and closing of the transaction are expected soon. Overall, the deal marks a major step for J&J in transforming cancer treatment through advanced cell-death technologies

Source: Fierce Biotech

India Launches World's First NorUDCA Drug 'NODUCA' for Fatty Liver Disease



India has introduced NODUCA, the world's first approved NorUDCA (nor-Ursodeoxycholic Acid) drug for treating metabolic fatty liver disease (MAFLD). Developed by Shilpa Medicare, the therapy offers powerful anti-inflammatory and anti-fibrotic benefits. Clinical trials showed significant improvements, including 83% fibrosis reversal and 90% normalization of liver enzymes within three months. The launch marks a breakthrough in liver-disease treatment and positions India as a global pioneer in NorUDCA therapy.

The drug also enhances bile flow and helps protect liver cells from toxin buildup. Its approval opens new possibilities for early-stage intervention in millions of undiagnosed MAFLD patients. NODUCA is expected to shape future global guidelines for fatty-liver management.

Source: Business standard.com

Pfizer Brings Rimegepant ODT to India for Advanced Migraine Relief



Pfizer has introduced Rimegepant ODT, a novel oral migraine therapy, in India for adults whose previous treatment with triptans was unsatisfactory. Rimegepant works by blocking the activity of Calcitonin Gene-Related Peptide (CGRP) — a key molecule involved in migraine pain — offering a modern, mechanism-based approach to relief. The drug is available in 75 mg orally-disintegrating tablets (ODT), which dissolve without water, making it convenient for quick use.

Rimegepant delivers rapid and sustained pain relief lasting up to 48 hours, and is not associated with medication-overuse headache, a common drawback of older migraine drugs. With the new launch, Pfizer aims to provide Indian migraine sufferers an effective alternative — particularly those who do not respond to conventional treatments — potentially improving quality of life and productivity.

Source: ET pharma

Novo Nordisk to Introduce Weight-Loss Drug ‘Poviztra’ in India



Source: Reuters.com

Novo Nordisk has announced plans to launch its new weight-loss drug Poviztra in India through an exclusive distribution partnership with Emcure Pharmaceuticals. Poviztra contains 2.4 mg of semaglutide, the same active ingredient used in the company’s globally recognized obesity treatment, Wegovy.

The collaboration aims to broaden access to clinically proven obesity therapies across India, with Emcure leveraging its national reach to expand availability beyond major urban centers. With the introduction of Poviztra, Novo Nordisk strengthens its position in the country’s growing metabolic-health market. Pricing details for the product are yet to be disclosed



Cipla acquires Inzpera Healthscience, aims to expand paediatric & wellness portfolio

Cipla is acquiring Inzpera for ₹110–111 crore to expand in paediatric wellness.

Inzpera adds strong child-health and nutrition products to Cipla’s portfolio.

The deal strengthens Cipla’s focus on wellness and high-growth segments

Source: The Economic Times



Glenmark Debuts Triple COPD Nebulized Treatment

Glenmark has launched the world’s first nebulized triple therapy for COPD in India.

The single-dose combo of Glycopyrronium, Formoterol, and Budesonide offers an easier option for patients who struggle with inhalers.

Source: Indianpharmaoutlook.com

STRATEGIC BUSINESS UPDATES



India's Pharma Sector Poised for Major Transformation by 2030

India's pharmaceutical sector is poised for major growth between 2026 and 2030, driven by rapid medical innovation and the arrival of advanced therapies for cancer, diabetes, heart disease, and metabolic and immune disorders. Many breakthrough treatments previously available only in developed nations are expected to enter the Indian market, improving patient outcomes and reducing the need for overseas care. With rising investment in R&D, clinical trials, and biotech partnerships, India's pharma market could reach USD 120–130 billion by 2030. Overall, the coming years may mark a transformative shift toward more accessible, personalized, and high-quality healthcare in India.

Source: Navbharattimes



MIP Proposal for APIs Aims at Self-Reliance but Alarms Small Manufacturers

The government is considering a Minimum Import Price (MIP) on key APIs like Penicillin-G, 6-APA and Amoxicillin to curb cheap Chinese imports and boost domestic manufacturing. Industry bodies warn this could sharply raise input costs, pushing up medicine prices and putting 10,000+ MSMEs (Micro, Small and Medium Enterprises) and nearly 2 lakh jobs at risk. Essential drugs, especially antibiotics, may see price hikes of up to 40% in government tenders. While the move aligns with India's self-reliance push under the PLI scheme, small pharma players caution that the policy may strain the sector without supportive measures.

Source: Economic Times

WORD SEARCH !!!!!!!

Search 10 Pharma companies

S U N P H A R M A X N D
A U R O B I N D O E A R
C I P L A G H Q Z V T R
B G L E N M A R K P C E
L S O I N Y T W U L O D
F U R C A D I L A M S D
P Q P Z T O R R E N T Y
A K M I B C V N E R L S
Z Y X J N O P Q R S U T
Z Y D U S A B C D E F G
M N O P Q R S T U V W X
A B C D E F G H I J K L



PGDM-Pharmaceutical Management

PGDM Program is a meticulously conceived industry oriented program, approved by AICTE, NBA accredited and Equivalent to MBA by AIU. It is a 2 Year Full Time Program consisting of 6 terms. PGDM-PM is a meticulously conceived industry oriented program, approved by AICTE. It offers a complete insight into the Pharmaceutical sector.

Editorial Team

Anchal Israni

anchal.israni24@ies.edu

Rohit Rane

rohit.rane24@ies.edu

Sanika Narvankar

sanika.narvankar24@ies.edu

Kiran Yadav

kiran.yadav24@ies.edu

Ajay Kharate

ajay.kharate24@ies.edu

Prapti Nagdeve

prapti.nagdeve25@ies.edu

Sunny Roy

sunny.roy25@ies.edu

Janhavi Narvekar

janhavi.narvekar25@ies.edu

Sachi Israni

sachi.israni25@ies.edu

Nishant Choudhari

nishant.choudhari25@ies.edu



General Enquiry Address: IES MCRC "Vishwakarma" M.D. Lotlikar Vidya Sankul, 791, S.

K. Marg, Bandra Reclamation, Mumbai - 400 050

Registrar office / Admin Office no. - 022 - 5000 1725/ 5000 1785

For any other enquiry - ies.mcrc@ies.edu/ registrar.mcrc@ies.edu